Identifying plasma metabolic characteristics of major depressive disorder, bipolar disorder, and schizophrenia in adolescents
© 2024. The Author(s)..
Major depressive disorder (MDD), bipolar disorder (BD), and schizophrenia (SCZ) are classified as major mental disorders and together account for the second-highest global disease burden, and half of these patients experience symptom onset in adolescence. Several studies have reported both similar and unique features regarding the risk factors and clinical symptoms of these three disorders. However, it is still unclear whether these disorders have similar or unique metabolic characteristics in adolescents. We conducted a metabolomics analysis of plasma samples from adolescent healthy controls (HCs) and patients with MDD, BD, and SCZ. We identified differentially expressed metabolites between patients and HCs. Based on the differentially expressed metabolites, correlation analysis, metabolic pathway analysis, and potential diagnostic biomarker identification were conducted for disorders and HCs. Our results showed significant changes in plasma metabolism between patients with these mental disorders and HCs; the most distinct changes were observed in SCZ patients. Moreover, the metabolic differences in BD patients shared features with those in both MDD and SCZ, although the BD metabolic profile was closer to that of MDD than to SCZ. Additionally, we identified the metabolites responsible for the similar and unique metabolic characteristics in multiple metabolic pathways. The similar significant differences among the three disorders were found in fatty acid, steroid-hormone, purine, nicotinate, glutamate, tryptophan, arginine, and proline metabolism. Interestingly, we found unique characteristics of significantly altered glycolysis, glycerophospholipid, and sphingolipid metabolism in SCZ; lysine, cysteine, and methionine metabolism in MDD and BD; and phenylalanine, tyrosine, and aspartate metabolism in SCZ and BD. Finally, we identified five panels of potential diagnostic biomarkers for MDD-HC, BD-HC, SCZ-HC, MDD-SCZ, and BD-SCZ comparisons. Our findings suggest that metabolic characteristics in plasma vary across psychiatric disorders and that critical metabolites provide new clues regarding molecular mechanisms in these three psychiatric disorders.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Translational psychiatry - 14(2024), 1 vom: 26. März, Seite 163 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Yin, Bangmin [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 28.03.2024 Date Revised 29.03.2024 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41398-024-02886-z |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370213882 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM370213882 | ||
003 | DE-627 | ||
005 | 20240330001451.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240328s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41398-024-02886-z |2 doi | |
028 | 5 | 2 | |a pubmed24n1355.xml |
035 | |a (DE-627)NLM370213882 | ||
035 | |a (NLM)38531835 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Yin, Bangmin |e verfasserin |4 aut | |
245 | 1 | 0 | |a Identifying plasma metabolic characteristics of major depressive disorder, bipolar disorder, and schizophrenia in adolescents |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 28.03.2024 | ||
500 | |a Date Revised 29.03.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024. The Author(s). | ||
520 | |a Major depressive disorder (MDD), bipolar disorder (BD), and schizophrenia (SCZ) are classified as major mental disorders and together account for the second-highest global disease burden, and half of these patients experience symptom onset in adolescence. Several studies have reported both similar and unique features regarding the risk factors and clinical symptoms of these three disorders. However, it is still unclear whether these disorders have similar or unique metabolic characteristics in adolescents. We conducted a metabolomics analysis of plasma samples from adolescent healthy controls (HCs) and patients with MDD, BD, and SCZ. We identified differentially expressed metabolites between patients and HCs. Based on the differentially expressed metabolites, correlation analysis, metabolic pathway analysis, and potential diagnostic biomarker identification were conducted for disorders and HCs. Our results showed significant changes in plasma metabolism between patients with these mental disorders and HCs; the most distinct changes were observed in SCZ patients. Moreover, the metabolic differences in BD patients shared features with those in both MDD and SCZ, although the BD metabolic profile was closer to that of MDD than to SCZ. Additionally, we identified the metabolites responsible for the similar and unique metabolic characteristics in multiple metabolic pathways. The similar significant differences among the three disorders were found in fatty acid, steroid-hormone, purine, nicotinate, glutamate, tryptophan, arginine, and proline metabolism. Interestingly, we found unique characteristics of significantly altered glycolysis, glycerophospholipid, and sphingolipid metabolism in SCZ; lysine, cysteine, and methionine metabolism in MDD and BD; and phenylalanine, tyrosine, and aspartate metabolism in SCZ and BD. Finally, we identified five panels of potential diagnostic biomarkers for MDD-HC, BD-HC, SCZ-HC, MDD-SCZ, and BD-SCZ comparisons. Our findings suggest that metabolic characteristics in plasma vary across psychiatric disorders and that critical metabolites provide new clues regarding molecular mechanisms in these three psychiatric disorders | ||
650 | 4 | |a Journal Article | |
700 | 1 | |a Cai, Yuping |e verfasserin |4 aut | |
700 | 1 | |a Teng, Teng |e verfasserin |4 aut | |
700 | 1 | |a Wang, Xiaolin |e verfasserin |4 aut | |
700 | 1 | |a Liu, Xueer |e verfasserin |4 aut | |
700 | 1 | |a Li, Xuemei |e verfasserin |4 aut | |
700 | 1 | |a Wang, Jie |e verfasserin |4 aut | |
700 | 1 | |a Wu, Hongyan |e verfasserin |4 aut | |
700 | 1 | |a He, Yuqian |e verfasserin |4 aut | |
700 | 1 | |a Ren, Fandong |e verfasserin |4 aut | |
700 | 1 | |a Kou, Tianzhang |e verfasserin |4 aut | |
700 | 1 | |a Zhu, Zheng-Jiang |e verfasserin |4 aut | |
700 | 1 | |a Zhou, Xinyu |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Translational psychiatry |d 2011 |g 14(2024), 1 vom: 26. März, Seite 163 |w (DE-627)NLM209970901 |x 2158-3188 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2024 |g number:1 |g day:26 |g month:03 |g pages:163 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41398-024-02886-z |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 14 |j 2024 |e 1 |b 26 |c 03 |h 163 |